Article Highlight | 16-Nov-2026

No drug yet slows Parkinson's disease. Blocking one neuronal receptor may change that

A Perspective in The Innovation maps why α-synuclein therapies keep falling short in trials and proposes blocking FAM171A2—the neuronal receptor that ferries pathological α-synuclein into neurons—as a new disease-modifying route

Innovation Press

More than 10 million people live with Parkinson's disease, a disorder in which Parkinson's medicines can steady the tremors but cannot stop the underlying decline. No therapy has yet been proven to slow the disease itself. In a Perspective in The Innovation, researchers at Huashan Hospital, Fudan University, take stock of every serious attempt to change that—and argue the most promising one may be to stop a misfolded protein from spreading between brain cells.

The obstacle is α-synuclein, a protein that normally helps neurons pass signals but, in Parkinson's disease, misfolds into sticky fibrils that spread from cell to cell with prion-like behavior. Most therapeutic attacks have aimed at these aggregates, and most have disappointed: the furthest-advanced antibody, prasinezumab, missed its main trial endpoint; small-molecule inhibitors still await clinical validation; and gene-editing approaches face safety and delivery hurdles. Mitochondrial-targeted drugs are only now reaching phase I trials, anti-inflammatory strategies have not paid off in patients, and cell replacement therapy—though two 2025 trials reported safety and preliminary efficacy for lab-grown dopamine neurons—remains too invasive for anything but late-stage disease.

The Perspective proposes attacking a different link in the chain: the doorway pathological α-synuclein uses to enter neurons. Building on the team's earlier work, it highlights FAM171A2, a neuronal membrane receptor that grabs fibrils by their tail with 1,000-fold higher affinity than it shows for harmless monomers. In mice, deleting the receptor in neurons curbed the spread of α-synuclein pathology, protected dopamine-producing cells, and eased motor deficits. Human evidence lines up too: FAM171A2 is abundant in patients' midbrains, its levels in cerebrospinal fluid track the burden of α-synuclein aggregates, and gene variants that raise its expression raise Parkinson's risk.

Crucially, blocking the doorway spares α-synuclein's normal job—a targeted strike that antibodies, which must grapple with the protein's many misfolded shapes, have struggled to make. To find a blocker, the team combined nuclear magnetic resonance with AlphaFold-based prediction to map the binding interface, screened more than 7,000 compounds in silico, and landed on bemcentinib, an experimental cancer drug candidate. Because bemcentinib poorly penetrates the blood–brain barrier, the team showed proof of principle by infusing it into the brains of mice, where it blocked fibril uptake, and laid out a medicinal-chemistry roadmap—scaffold hopping, nanocarriers, prodrugs—to produce brain-penetrant derivatives.

The authors are candid about the caveats: FAM171A2's normal functions are poorly understood, its safety as a drug target is untested, and efficacy against the oligomeric forms of α-synuclein still needs checking. Yet because α-synuclein aggregation underlies 95% of Parkinson's cases—and drives related disorders such as dementia with Lewy bodies and multiple system atrophy—a working FAM171A2 blocker could reach most patients. For a disease that medicine has only been able to quiet, not stop, the doorway is now a target.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.